Gloucester Pharmaceuticals - Top 20 VC deals of 2008

Gloucester Pharmaceuticals, Fiercebiotech's top venture capital deals of 2008Company: Gloucester Pharmaceuticals
Based: Cambridge, MA
Amount: $47.13M

Investors: Prospect Venture Partners, Individuals, ProQuest Investments, CIBC Capital Partners, Undisclosed Firm

Scoop: Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through regulatory approval and commercialization. It's most advanced drug program is romidepsin, a histone deacetylase (HDAC) inhibitor in Phase III trials for T-cell lymphomas.

Gloucester Pharmaceuticals - Top 20 VC deals of 2008
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.